Massive therapy and autologous bone marrow transplantation in pediatric and young adults Burkitt's lymphoma (30 courses on 28 patients: a 5-year experience)

Philip, T, Biron, P, Philip, I, Favrot, M, Souillet, G, Frappaz, D, Jaubert, J, Bordigoni, P, Bernard, JL, Laporte, JP, Lemevel, A, Plouvier, E, Marguerite, G, Pinkerton, R, Brizard, CP, Freycon, F, Forster, HK, Philippe, N and Brunatmentigny, M (1986) Massive therapy and autologous bone marrow transplantation in pediatric and young adults Burkitt's lymphoma (30 courses on 28 patients: a 5-year experience). European Journal of Cancer and Clinical Oncology, 22 8: 1015-1027. doi:10.1016/0277-5379(86)90070-2


Author Philip, T
Biron, P
Philip, I
Favrot, M
Souillet, G
Frappaz, D
Jaubert, J
Bordigoni, P
Bernard, JL
Laporte, JP
Lemevel, A
Plouvier, E
Marguerite, G
Pinkerton, R
Brizard, CP
Freycon, F
Forster, HK
Philippe, N
Brunatmentigny, M
Title Massive therapy and autologous bone marrow transplantation in pediatric and young adults Burkitt's lymphoma (30 courses on 28 patients: a 5-year experience)
Journal name European Journal of Cancer and Clinical Oncology   Check publisher's open access policy
ISSN 0277-5379
Publication date 1986
Sub-type Article (original research)
DOI 10.1016/0277-5379(86)90070-2
Volume 22
Issue 8
Start page 1015
End page 1027
Total pages 13
Language eng
Subject 2730 Oncology
Abstract A 5-yr experience of massive therapy and autologous bone marrow transplantation (ABMT) for Burkitt's lymphoma is reviewed. Thirty courses were given to 28 patients. Three patients were in resistant relapse and all three died before day 54 post ABMT. Thirteen patients were in non-resistant relapse and seven are alive with non-evidence of disease (NED). All three patients grafted in partial remission (PR) are alive NED including two with initial central nervous system (CNS) disease. Nine patients were grafted in 1st complete remission (CR) either because of long delay to achieve CR [3] or as consolidation in those with initial CNS involvement [5] or leukaemia [1]. Three of these nine are alive including 2 3 with a long delay to CR and 1 5 initial CNS. The overall survival NED for the 28 patients is 46%. The median observation time post ABMT, 22 months. Clear indications for ABM T in BL are in our opinion restricted to about 20% of the patients: non-resistant relapses and PR after initial induction therapy. Massive therapy as consolidation of 1st CR after initial CNS involvement and in resistant relapses should still be considered as experimental. In 14 patients whose marrow was purged there is laboratory evidence suggesting that the purging procedures used in this study may have been incomplete. Purging techniques still require perfection at a laboratory level and their rationale should not be judged on the basis of incomplete procedures.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Article (original research)
Collections: ResearcherID Downloads
Scopus Import
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 48 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 25 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 08 Jul 2016, 17:57:52 EST by System User